DanaFarber Cancer Institute Newswire (Page 7)

DanaFarber Cancer Institute Newswire (Page 7)

Comprehensive Real-Time News Feed for DanaFarber Cancer Institute. (Page 7)

Results 121 - 140 of 1,373 in DanaFarber Cancer Institute

  1. Spotlight Innovation Appoints Senior Vice President Of Regulatory Affairs And ComplianceRead the original story

    Dec 7, 2016 | BioSpace

    Dr. Edwin will provide leadership for all U.S. and international regulatory matters including strategic planning for regulatory approvals, preparation of regulatory submissions, serving as the primary contact with the FDA and other regulatory authorities, and ensuring compliance with regulatory requirements. Dr. Edwin has two decades of regulatory affairs, regulatory compliance and quality systems experience, and has been a key member in the development of infectious disease, oncology and cardiology products that have secured regulatory approval for commercialization.

    Comment?

  2. Brain metastasis persists despite improved targeted treatment for HER2 breast cancerRead the original story w/Photo

    Dec 8, 2016 | PhysOrg Weblog

    While new targeted treatments developed across the past two decades have led to dramatic survival improvements for women with HER2-positive metastatic breast cancer, University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators report that rates of breast cancer brain metastasis for women with this disease have not substantially declined. "We need better therapies to prevent brain metastasis," said the study's senior author Carey Anders, MD, a UNC Lineberger member, an associate professor in the UNC School of Medicine, and a co-founder of a UNC Brain Metastases Specialty Clinic.

    Comment?

  3. I've used a meditation app loved by Wall Streeters and Olympic...Read the original story w/Photo

    Dec 7, 2016 | Silicon Alley Insider

    Over the past eight months, I've had fun being the obnoxious guy who tells everyone he meditates every day. Ever since I decided to try out the guided-meditation app Headspace last December after hearing about it on Tim Ferriss' podcast, I've been much more aware of my thoughts and emotions, and with a few exceptions I've been much calmer and more collected in times of stress.

    Comment?

  4. Celgene Corporation, Dana-Farber Cancer Institute and University of...Read the original story

    Dec 3, 2016 | Customer Interaction Solutions

    Celgene Corporation , Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences today announced the creation of the Myeloma Genome Project, a collaborative initiative aimed at compiling the largest dataset of high-quality genomic and clinical data to identify distinct molecular disease segments within multiple myeloma to advance diagnosis, prognosis and treatment of multiple myeloma patients. The initiative seeks to develop clinically relevant tests.

    Comment?

  5. Genetic classification offers guide to stem cell transplantation for...Read the original story

    Dec 3, 2016 | PressReleasePoint

    A blood test can indicate whether some patients with myelodysplastic syndrome are likely to benefit from a stem cell transplant and, if so, whether the transplant should involve high or moderate doses of chemotherapy and/or radiation therapy. The findings are according to study results to be presented by Dana-Farber Cancer Institute investigators at the 58th annual meeting of the American Society of Hematology .

    Comment?

  6. Aduro Biotech Presents Preclinical Data Supporting Clinical...Read the original story

    Dec 3, 2016 | World News Report

    Aduro Biotech, Inc. , a biopharmaceutical company with three distinct immunotherapy technologies, today announced the presentation of data from preclinical studies supporting the clinical development of the company's proprietary monoclonal antibody BION-1301, a humanized anti-APRIL antibody for the treatment of multiple myeloma.  Data from these in vivo and in vitro preclinical studies demonstrated that BION-1301 effectively neutralized APRIL, preventing its binding to BCMA , an essential receptor expressed on multiple myeloma cells.  Based on the mechanism of action and anti-tumor activity observed in earlier preclinical studies with the parental anti-APRIL antibody, hAPRIL.01A, BION-1301 has the potential to inhibit multiple myeloma tumor growth, survival and chemoresistance.  These data, which will be highlighted in a poster presentation at the 58th American Society of ... (more)

    Comment?

  7. Acetylon Announces Upcoming Scientific Presentations on the Use of...Read the original story

    Dec 2, 2016 | Customer Interaction Solutions

    Acetylon Pharmaceuticals, Inc. , the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that multiple posters and oral presentations on its preclinical and clinical programs will be presented at the American Society of Hematology Annual Meeting , held from December 3-6 in San Diego, California. "The lineup of data presentations for Acetylon assets at ASH includes exciting advancements in our selective HDAC1,2 inhibitor preclinical program in sickle cell disease and beta-thalassemia and selective HDAC6 inhibitor preclinical programs in multiple myeloma, lymphoma, and leukemia.

    Comment?

  8. Bradley Named ABCD HeroRead the original story

    Dec 2, 2016 | Charlestown Patriot-Bridge

    Peggy Bradley has long been a recognizable figure in Charlestown through her work with the Charlestown Preservation Society, Charlestown Sprouts and Charlestown Neighborhood Council. Bradley received the honor at ABCD's annual Community Heroes Gala at the Copley Marriott.

    Comment?

  9. Scientists discover unique genomic changes integral to testicular cancer developmentRead the original story w/Photo

    Dec 1, 2016 | Medical News

    Researchers led by scientists at Dana-Farber Cancer Institute say they have identified unique genomic changes that may be integral to testicular cancer development and explain why the great majority are highly curable with chemotherapy - unlike most solid tumors. The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy, according to a report in Nature.

    Comment?

  10. Scientists Identify Unique Genomic Features in Testicular CancerRead the original story

    Dec 1, 2016 | Newswise

    Researchers led by scientists at Dana-Farber Cancer Institute say they have identified unique genomic changes that may be integral to testicular cancer development and explain why the great majority are highly curable with chemotherapy - unlike most solid tumors. The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy, according to a report in Nature.

    Comment?

  11. The first analysis of Ewing's sarcoma methyloma opens doors to new treatmentsRead the original story w/Photo

    Dec 1, 2016 | PhysOrg Weblog

    This is a graphical abstract. Researchers of the Sarcoma research group of the Bellvitge Biomedical Research Institute , led by Dr. Oscar Martinez-Tirado, have first described the methylation profile of Ewing's sarcoma , a cancer of bone and soft tissues that mainly affects children and teenagers.

    Comment?

  12. Sean Parker is partnering with the Cancer Research Institute to find a cancer vaccineRead the original story w/Photo

    Dec 1, 2016 | TechCrunch

    You are about to activate our Facebook Messenger news bot. Once subscribed, the bot will send you a digest of trending stories once a day.

    Comment?

  13. Genome analysis reveals germ cell cancers distinct rootsRead the original story

    Nov 30, 2016 | PressReleasePoint

    Germ cell tumors are growths that arise from reproductive cells, most commonly in the testes. For young men diagnosed with testicular germ cell tumor , the most common type of testicular cancer, the news comes with a silver lining: Most patients with germ cell tumors can be cured with standard chemotherapy.

    Comment?

  14. Preserving fertility in girls and young women with cancer 'haphazard', say expertsRead the original story w/Photo

    Nov 30, 2016 | PhysOrg Weblog

    Preserving fertility in girls and young women with cancer is "haphazard" across the UK, argue experts in an editorial published by The BMJ today. Professor Richard Anderson and consultant gynaecologist Melanie Davies explain that advances in the treatment of cancer in children and young adults have meant that more survivors are living with the long term consequences of treatment, and loss of fertility is a big concern.

    Comment?

  15. Screening to blame for thyroid cancer 'epidemic' in South KoreaRead the original story w/Photo

    Nov 30, 2016 | PhysOrg Weblog

    The current "epidemic" of thyroid cancer in South Korea is due to an increase in the detection of small tumours, most likely as a result of overdetection by screening, finds a study published by The BMJ today. The researchers say concerted efforts are needed at a national level to reduce unnecessary thyroid ultrasound examinations in the general population.

    Comment?

  16. New Hampshire Theatre Project presents the Winter Solstice in Legend and SongRead the original story w/Photo

    Nov 28, 2016 | BroadwayWorld.com

    New Hampshire Theatre Project honors the winter solstice with master storyteller Diane Edgecomb, Celtic harper Margot Chamberlain, and multi-instrumentalist Tom Megan . Celebrate the longest night of the year with haunting legends of light, entertaining tales and traditional music and song.

    Comment?

  17. As the Avon sunflowers grow, so grows the movement; Prayers from Maria marks $1 million in grantsRead the original story w/Photo

    Nov 28, 2016 | Cleveland.com

    The sunflowers that blanket Maria's 50-acre Field of Hope in Avon may have gone to seed again for this year, but the mission of the Prayers from Maria Foundation grew a milestone. The foundation announced it has, since its inception, awarded $1 million in grants to fund global research into a type of brain tumor so often fatal to children.

    Comment?

  18. GTx, Inc. Release: Enobosarm Meets Pre-Specified Primary Efficacy...Read the original story

    Nov 27, 2016 | BioSpace

    GTx, Inc. today announced that enobosarm achieved the pre-specified primary efficacy endpoint in the 9 mg dose cohort from patients in both stage 1 and the ongoing stage 2 of its Phase 2 clinical trial in women with advanced, estrogen receptor positive , androgen receptor positive breast cancer. The primary efficacy endpoint requires at least nine patients to achieve clinical benefit, defined as either a complete response, partial response or stable disease, as measured by Response Evaluation Criteria in Solid Tumors at 24 weeks of treatment.

    Comment?

  19. Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing...Read the original story

    Nov 28, 2016 | Customer Interaction Solutions

    GTx, Inc. today announced that enobosarm achieved the pre-specified primary efficacy endpoint in the 9 mg dose cohort from patients in both stage 1 and the ongoing stage 2 of its Phase 2 clinical trial in women with advanced, estrogen receptor positive , androgen receptor positive breast cancer. The primary efficacy endpoint requires at least nine patients to achieve clinical benefit, defined as either a complete response, partial response or stable disease, as measured by Response Evaluation Criteria in Solid Tumors at 24 weeks of treatment.

    Comment?

  20. OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Triple Negative Breast CancerRead the original story

    Nov 28, 2016 | Customer Interaction Solutions

    OncoPep, Inc. announced that a Phase 1b clinical trial is underway to evaluate PVX-410, a multi-peptide therapeutic cancer vaccine, as an adjuvant treatment in patients who have completed all planned therapy for stage II or III triple negative breast cancer . The study, led by Steven Isakoff, M.D., Ph.D. at Massachusetts General Hospital, will assess the safety and tolerability of PVX-410 in combination with the checkpoint inhibitor durvalumab.

    Comment?